Diabetes Mellitus, Type 2 Clinical Trial
Official title:
A Multicentre Controlled and Randomized Study Assessing the Effect of Dulaglutide add-on to Dietary Reinforcement Versus Dietary Reinforcement Alone in Patients With Type 2 Diabetes and Carriers of a Non-alcoholic Steatohepatitis
GLP-1 analogues represent new treatments in diabetes that cause weight loss. Their effect on
NASH in humans is unknown. A decrease in Alanine Aminotransferase (ALT) has been reported in
pooled Exenatide/Placebo and Liraglutide/Placebo studies. More recently, LEAN study has shown
that Liraglutide will result in improvements in liver histology in patients with NASH. It
should be of high interest to investigate the effect of another GLP-1 Agonist as effective as
Liraglutide, i.e. Dulaglutide in NASH.
Dulaglutide is one of the five GLP-1 receptor agonists approved for type 2 diabetes mellitus
(T2DM). It is an effective treatment because it is dosed once-weekly, provides HbA1c
reduction similar to Liraglutide, weight reduction similar to Exenatide, and has an adverse
effect profile similar to other GLP-1 receptor agonists. Reduction in body weight was
observed in patients treated with Dulaglutide, irrespective of nausea and/or vomiting.The
search for a direct effect of Dulaglutide on liver fat overload in patients with type2
diabetes is required before considering the effectiveness of this treatment in NASH in
diabetic populations. No current GLP-1 study has been designed with a control group with the
same weight loss than as in the treatment group.
Primary objective: The investigators aim to study the effect of Dulaglutide 1.5 mg
(TRULICITY®) add-on to dietary reinforcement after 52 weeks of treatment, on the improvement
of liver histology compared to dietary reinforcement alone in patients with type 2 diabetes
and carriers of non-alcoholic steatohepatitis.
Secondary objectives:
- After 52 weeks of treatment, to assess the effect of dulaglutide (TRULICITY®) add-on to
dietary reinforcement on Fibrosis score, Transaminase levels, body composition as
measured by dual energy X-ray absorptiometry, lipid profile, glycemic control and
weight. The effect of the treatment will also be assessed on quality of life.
- At 24 weeks after completion of the treatment, to assess the sustainability of
dulaglutide (TRULICITY®) treatment add-on to dietary reinforcement on ALT and AST rates
as well as on weight.
This is a multicentre, open, prospective, randomized, controlled dietary reinforcement study.
- Treatment Group: dulaglutide (TRULICITY®) subcutaneous administration, one weekly
injection, in a dose of 1.5 mg of dulaglutide in combinaison with reinforced dietary
monitoring as same as control group.
- Control group: reinforced dietary monitoring with frequent dietary consultations, based
on AHA recommendations:
All patients are monitored in the same way for dietary reinforcement.
The study will be conducted over the course of 80 weeks in 3 periods (13 visits):
- Period I: Run-in phase of 4 weeks
- Period II: Treatment phase of 52 weeks
- Period III: Follow-up phase of 24 weeks. The patient must return to the study centre to
assess whether the response to treatment is time-dependent.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |